|
1
|
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
|
N Engl J Med
|
2011
|
18.99
|
|
2
|
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
|
Sci Transl Med
|
2011
|
12.58
|
|
3
|
Chimeric antigen receptor T cells for sustained remissions in leukemia.
|
N Engl J Med
|
2014
|
8.21
|
|
4
|
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
|
N Engl J Med
|
2014
|
7.64
|
|
5
|
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.
|
Blood
|
2010
|
5.79
|
|
6
|
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
|
Nat Med
|
2005
|
3.65
|
|
7
|
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.
|
Sci Transl Med
|
2012
|
3.29
|
|
8
|
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
|
Blood
|
2013
|
2.91
|
|
9
|
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.
|
Blood
|
2004
|
2.90
|
|
10
|
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
|
Blood
|
2003
|
2.83
|
|
11
|
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
|
N Engl J Med
|
2015
|
2.77
|
|
12
|
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
|
Cancer Res
|
2010
|
2.64
|
|
13
|
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function.
|
Blood
|
2004
|
2.63
|
|
14
|
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.
|
Blood
|
2005
|
2.39
|
|
15
|
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.
|
Blood
|
2004
|
2.28
|
|
16
|
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
|
Cancer Res
|
2007
|
2.25
|
|
17
|
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.
|
Sci Transl Med
|
2011
|
2.14
|
|
18
|
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
|
Sci Transl Med
|
2013
|
2.07
|
|
19
|
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
|
Sci Transl Med
|
2011
|
2.04
|
|
20
|
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells.
|
Mol Ther
|
2009
|
1.97
|
|
21
|
CD28 costimulation is essential for human T regulatory expansion and function.
|
J Immunol
|
2008
|
1.86
|
|
22
|
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.
|
Mol Ther
|
2004
|
1.80
|
|
23
|
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
|
Blood
|
2010
|
1.77
|
|
24
|
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.
|
Blood
|
2010
|
1.66
|
|
25
|
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.
|
Blood
|
2012
|
1.64
|
|
26
|
Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection.
|
J Virol
|
2008
|
1.63
|
|
27
|
Adoptive immunotherapy for cancer or viruses.
|
Annu Rev Immunol
|
2014
|
1.61
|
|
28
|
Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.
|
Mol Ther
|
2008
|
1.47
|
|
29
|
A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.
|
Virology
|
2008
|
1.45
|
|
30
|
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.
|
Hum Gene Ther
|
2010
|
1.40
|
|
31
|
Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system.
|
Blood
|
2005
|
1.40
|
|
32
|
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.
|
Clin Cancer Res
|
2009
|
1.38
|
|
33
|
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.
|
Oncoimmunology
|
2013
|
1.37
|
|
34
|
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.
|
Blood
|
2009
|
1.35
|
|
35
|
Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1.
|
PLoS Biol
|
2010
|
1.35
|
|
36
|
CD28-mediated regulation of multiple myeloma cell proliferation and survival.
|
Blood
|
2007
|
1.31
|
|
37
|
Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.
|
Hum Gene Ther
|
2005
|
1.30
|
|
38
|
Gene expression characteristics of CD28null memory phenotype CD8+ T cells and its implication in T-cell aging.
|
Immunol Rev
|
2005
|
1.28
|
|
39
|
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
|
Blood
|
2010
|
1.23
|
|
40
|
Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation.
|
Biol Blood Marrow Transplant
|
2007
|
1.18
|
|
41
|
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.
|
Cancer
|
2012
|
1.18
|
|
42
|
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
|
Cancer Immunol Res
|
2013
|
1.14
|
|
43
|
Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.
|
Hum Gene Ther
|
2013
|
1.14
|
|
44
|
Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program.
|
Cytotherapy
|
2009
|
1.13
|
|
45
|
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.10
|
|
46
|
Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.
|
J Transl Med
|
2011
|
1.10
|
|
47
|
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
|
J Infect Dis
|
2002
|
1.07
|
|
48
|
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
|
Clin Cancer Res
|
2003
|
1.07
|
|
49
|
A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells.
|
Cancer Res
|
2004
|
1.06
|
|
50
|
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
|
Cancer Immunol Immunother
|
2011
|
1.06
|
|
51
|
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.
|
Autophagy
|
2010
|
1.04
|
|
52
|
Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
|
Immunol Res
|
2008
|
1.02
|
|
53
|
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.
|
J Immunother
|
2012
|
1.02
|
|
54
|
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
|
Clin Cancer Res
|
2014
|
1.01
|
|
55
|
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
|
Clin Cancer Res
|
2013
|
1.01
|
|
56
|
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
|
Blood
|
2013
|
0.99
|
|
57
|
Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
|
J Immunother
|
2011
|
0.98
|
|
58
|
Engineered T cells for cancer therapy.
|
Cancer Immunol Immunother
|
2014
|
0.95
|
|
59
|
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
|
Blood
|
2012
|
0.90
|
|
60
|
Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma.
|
Clin Cancer Res
|
2012
|
0.88
|
|
61
|
Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.
|
J Transl Med
|
2011
|
0.88
|
|
62
|
Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs.
|
Transplantation
|
2006
|
0.87
|
|
63
|
Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons.
|
Clin Immunol
|
2004
|
0.86
|
|
64
|
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.84
|
|
65
|
Adoptive T-cell therapy for malignant disorders.
|
Haematologica
|
2008
|
0.81
|
|
66
|
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
|
Clin Cancer Res
|
2011
|
0.79
|
|
67
|
Innovation and opportunity for chimeric antigen receptor targeted T cells.
|
Cytotherapy
|
2013
|
0.77
|
|
68
|
Cell therapy medical tourism: time for action.
|
Cytotherapy
|
2010
|
0.76
|
|
69
|
Cancer Killers.
|
Sci Am
|
2017
|
0.75
|
|
70
|
Convergence of gene and cell therapy.
|
Regen Med
|
2012
|
0.75
|